Please see our listing of events below, or contact us at (802) 656-4414.
Please note the this schedule is subject to change. New events are added continually, so be sure to check back regularly.
UVM Cancer Center Public Event Provider/Researcher Event Community Event
Friday, 2/12
12-1PM
Zoom: 942 5336 3648
Presented by Ryan S. McGinnis, PhDAssistant Professor and Director │ Biomedical Engineering ProgramDepartment of Electrical and Biomedical Engineering, University of Vermont
The presentation will introduce UVM’s Center for Biomedical Innovation and highlight several ongoing projects that aim to develop new technologies for remote assessment and intervention. A new approach for rapid and objective fall risk characterization and a mobile application for providing physiological biofeedback to help manage panic attacks will be discussed.
Add to my calendarJoin Zoom Meeting https://uvmcom.zoom.us/j/94253363648Dial 646 876 9923Meeting ID 942 5336 3648
Please Contact Jennifer.Smith@med.uvm.edu with questions
Monday, 3/22
3-4:00PM
Zoom: 971 9082 1580
Featuring Leslie V. Parise, PhD Dean, College of Agriculture and Life Sciences Interim Director, UVM Extension Professor, Microbiology and Molecular Genetics University of Vermont
CIB1 is a ubiquitously expressed, intracellular protein that appears to be an excellent target in multiple cancers due to its regulation of key oncogenic pathways. The Parise lab originally cloned, sequenced and named the small protein CIB1. We solved its 3-dimensional crystal structure, which has informed our drug targeting studies. We created and characterized a CIB1 knockout mouse, which allowed us to determine that disrupting CIB1 function can prevent tumor-induced angiogenesis and protect against cardiac hypertrophy. We completed several studies showing how CIB1 promotes tumor cell survival and proliferation by regulating major oncogenic pathways. Conversely, CIB1 depletion induces massive death in susceptible tumor cells via distinct mechanisms depending on the tumor cell types. Tumor cell death was further enhanced in combination with docetaxel or TRAIL. We have also validated CIB1 as a drug target by depleting it in tumors in vivo, derived from a human triple negative breast cancer (TNBC) cell line in mouse xenografts. Finally, we have made extensive progress in screening and identifying small molecule CIB1 inhibitors with subsequent validation, in collaboration with UNC’s Center for Integrative Chemical Biology and Drug Discovery. We have concluded that combination therapies targeting CIB1 could prove to be a safe and efficacious in treating TNBC and potentially other cancers.
Monday 3/22 @ 3-4:00PM
Zoom Meeting Link:https://uvmcom.zoom.us/j/97190821580 Zoom Meeting ID: 971 9082 1580